Death-inducing functions of ligands of the tumor necrosis factor family: a Sanhedrin verdict.

[1]  G. Evan,et al.  p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice , 1998, Current Biology.

[2]  S. Nagata,et al.  Downregulation of Fas ligand by shedding , 1998, Nature Medicine.

[3]  J C Reed,et al.  A Single BIR Domain of XIAP Sufficient for Inhibiting Caspases* , 1998, The Journal of Biological Chemistry.

[4]  D. Goeddel,et al.  FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. , 1998, Science.

[5]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[6]  V. Dixit,et al.  Caspase-9, Bcl-XL, and Apaf-1 Form a Ternary Complex* , 1998, The Journal of Biological Chemistry.

[7]  Stefan Grimm,et al.  The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal , 1998 .

[8]  Y. Tsujimoto,et al.  Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  John Calvin Reed,et al.  The Mitochondrial F0F1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammalian cells. , 1998, Molecular cell.

[10]  John Calvin Reed,et al.  Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast. , 1998, Molecular cell.

[11]  Kenneth G. C. Smith,et al.  A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes , 1998, The EMBO journal.

[12]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[13]  Sten Orrenius,et al.  Injected cytochrome c induces apoptosis , 1998, Nature.

[14]  S. Nagata,et al.  Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis , 1998, Nature.

[15]  S. Nagata,et al.  A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD , 1998, Nature.

[16]  E. Cheng,et al.  Conversion of Bcl-2 to a Bax-like death effector by caspases. , 1997, Science.

[17]  A. Gurney,et al.  A novel receptor for Apo2L/TRAIL contains a truncated death domain , 1997, Current Biology.

[18]  C. Smith,et al.  The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.

[19]  P. Golstein.  Cell death: TRAIL and its receptors. , 1997, Current biology : CB.

[20]  M. V. Heiden,et al.  Bcl-xL Regulates the Membrane Potential and Volume Homeostasis of Mitochondria , 1997, Cell.

[21]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[22]  D. Baltimore,et al.  NF-κB Activation: The IκB Kinase Revealed? , 1997, Cell.

[23]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[24]  P. Branton,et al.  p28 Bap31, a Bcl-2/Bcl-XL- and Procaspase-8–associated Protein in the Endoplasmic Reticulum , 1997, The Journal of cell biology.

[25]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[26]  G Waksman,et al.  Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Trask,et al.  MRIT, a novel death-effector domain-containing protein, interacts with caspases and BclXL and initiates cell death. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[29]  R. Dubose,et al.  Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.

[30]  M. Hengartner.  Apoptosis CED-4 is a stranger no more , 1997, Nature.

[31]  R. Gentz,et al.  An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.

[32]  Y. Goltsev,et al.  CASH, a Novel Caspase Homologue with Death Effector Domains* , 1997, The Journal of Biological Chemistry.

[33]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[34]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[35]  N. Thornberry,et al.  Caspases: killer proteases. , 1997, Trends in biochemical sciences.

[36]  S. Srinivasula,et al.  FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis* , 1997, The Journal of Biological Chemistry.

[37]  F Gambale,et al.  Inhibition of Bax channel-forming activity by Bcl-2. , 1997, Science.

[38]  Margot Thome,et al.  Inhibition of death receptor signals by cellular FLIP , 1997, Nature.

[39]  Guy S. Salvesen,et al.  X-linked IAP is a direct inhibitor of cell-death proteases , 1997, Nature.

[40]  S. Seshagiri,et al.  Caenorhabditis elegans CED-4 stimulates CED-3 processing and CED-3-induced , 1997, Current Biology.

[41]  R. Weichselbaum,et al.  Role for Bcl-xL as an inhibitor of cytosolic cytochrome C accumulation in DNA damage-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  C. Riccardi,et al.  A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  D. Goeddel,et al.  Casper is a FADD- and caspase-related inducer of apoptosis. , 1997, Immunity.

[44]  J C Reed,et al.  Channel formation by antiapoptotic protein Bcl-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Xiaodong Wang,et al.  DFF, a Heterodimeric Protein That Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis , 1997, Cell.

[46]  C. Thompson,et al.  Bcl-x(L) can inhibit apoptosis in cells that have undergone Fas-induced protease activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Wallach,et al.  Cell death induction by TNF: a matter of self control. , 1997, Trends in biochemical sciences.

[48]  V. Dixit,et al.  Fas-associated Death Domain Protein Interleukin-1β-converting Enzyme 2 (FLICE2), an ICE/Ced-3 Homologue, Is Proximally Involved in CD95- and p55-mediated Death Signaling* , 1997, The Journal of Biological Chemistry.

[49]  S. Fesik,et al.  Identification of a novel regulatory domain in Bcl‐xL and Bcl‐2 , 1997, The EMBO journal.

[50]  A. Chinnaiyan,et al.  Interaction of CED-4 with CED-3 and CED-9: A Molecular Framework for Cell Death , 1997, Science.

[51]  G. Núñez,et al.  Interaction and Regulation of Subcellular Localization of CED-4 by CED-9 , 1997, Science.

[52]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[53]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[54]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[55]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[56]  S. Srinivasula,et al.  CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. , 1997, Cancer research.

[57]  S. Nagata,et al.  Apoptosis by Death Factor , 1997, Cell.

[58]  Andy J. Minn,et al.  Bcl-xL forms an ion channel in synthetic lipid membranes , 1997, Nature.

[59]  Vishva M. Dixit,et al.  RAIDD is a new 'death' adaptor molecule , 1997, Nature.

[60]  D. Wallach.  A decade of accumulated knowledge and emerging answers. The 6th international congress on TNF Rhodes, Greece. May 1996. , 1996, European cytokine network.

[61]  D. Goeddel,et al.  The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  John Calvin Reed,et al.  Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.

[63]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[64]  David Baltimore,et al.  An Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death , 1996, Science.

[65]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[66]  B. Seed,et al.  RIP mediates tumor necrosis factor receptor 1 activation of NF‐kappaB but not Fas/APO‐1‐initiated apoptosis. , 1996, The EMBO journal.

[67]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[68]  Michael Karin,et al.  Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.

[69]  Guido Kroemer,et al.  Mitochondria and programmed cell death: back to the future , 1996, FEBS letters.

[70]  R. Flavell,et al.  Expansion or Elimination of B Cells In Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor , 1996, Cell.

[71]  R. Gottlieb,et al.  Loss of Function of Cytochrome c in Jurkat Cells Undergoing Fas-mediated Apoptosis* , 1996, The Journal of Biological Chemistry.

[72]  D. Andrews,et al.  Bcl‐2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types. , 1996, The EMBO journal.

[73]  S. Srinivasula,et al.  In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[75]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[76]  D. Goeddel,et al.  The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[77]  David Wallach,et al.  Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death , 1996, Cell.

[78]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[79]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[80]  D. Vaux,et al.  Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[81]  John Calvin Reed,et al.  A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection , 1996, The Journal of experimental medicine.

[82]  M. Jäättelä,et al.  A20 zinc finger protein inhibits TNF and IL-1 signaling. , 1996, Journal of immunology.

[83]  H. Engelmann,et al.  A novel function of CD40: induction of cell death in transformed cells , 1996, The Journal of experimental medicine.

[84]  Mike Rothe,et al.  The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins , 1995, Cell.

[85]  R. Black,et al.  A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. , 1995, Journal of immunology.

[86]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[87]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[88]  S. Dower,et al.  Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. , 1995, Blood.

[89]  M. Tewari,et al.  Activation of the B-cell Surface Receptor CD40 Induces A20, a Novel Zinc Finger Protein That Inhibits Apoptosis (*) , 1995, The Journal of Biological Chemistry.

[90]  John Calvin Reed,et al.  FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.

[91]  V. Dixit,et al.  The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. , 1992, The Journal of biological chemistry.

[92]  N. Matthews.  Anti-tumour cytotoxin produced by human monocytes: studies on its mode of action. , 1983, British Journal of Cancer.

[93]  J. Hibbs,et al.  Injury of neoplastic cells by murine macrophages leads to inhibition of mitochondrial respiration. , 1980, The Journal of clinical investigation.

[94]  R. Yamamoto,et al.  The human LT system. V. A comparison of the relative lytic effectiveness of various MW human LT classes on 51Cr-labeled allogeneic target cells in vitro: enhanced lysis by LT complexes associated with Ig-like receptor(s). , 1979, Cellular immunology.

[95]  T. Pysher,et al.  Human lymphotoxin obtained from established lymphoid lines: purification characteristics and inhibition by anti-immunoglobulin. , 1974, Journal of immunology.

[96]  G. Granger,et al.  Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. , 1968, Journal of immunology.

[97]  B. Waksman,et al.  CYTOTOXICITY MEDIATED BY SOLUBLE ANTIGEN AND LYMPHOCYTES IN DELAYED HYPERSENSITIVITY , 1968, The Journal of experimental medicine.